Compare Novartis AG (NVS) vs Quanta Services Inc (PWR) Price & Performance

Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.

Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.

Quanta Services (PWR) trades at $685.33, down 4.76% on the day, but maintains a bullish technical trend with strong analyst support. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, with net income reaching $1.03B. The company benefits from a record $53B backlog and positive earnings surprises, though valuation multiples like a P/E of 80.21 suggest premium pricing. Recent news highlights PWR's role in AI infrastructure and data center spending, driving investor optimism.

Outlook remains positive given strong earnings beats and sector tailwinds, but high valuation and execution risks from rapid expansion pose challenges. Analysts see 26.5% upside to a $802.08 consensus target, with no sell ratings. Risks include margin pressure and macroeconomic sensitivity, yet institutional bullishness and operational momentum support long-term growth potential.